Select Publications
Book Chapters
2023, 'Chapter 8 Pharmacotherapy', in Osteoarthritis Health Professional Training Manual, Elsevier, pp. 125 - 145, http://dx.doi.org/10.1016/b978-0-323-99269-5.00006-2
,2022, 'Pharmacotherapy', in Osteoarthritis Health Professional Training Manual, pp. 125 - 145, http://dx.doi.org/10.1016/B978-0-323-99269-5.00006-2
,2019, 'Disease-Modifying Anti-rheumatic Drugs', in Nijkamp and Parnham’s Principles of Immunopharmacology: Fourth revised and extended edition, pp. 709 - 750, http://dx.doi.org/10.1007/978-3-030-10811-3_34
,2018, 'Usability of Reports Generated by a Computerised Dose Prediction Software', in Connecting the System to Enhance the Practitioner and Consumer Experience in Healthcare, IOS Press, pp. 27 - 32, http://dx.doi.org/10.3233/978-1-61499-890-7-27
,2016, 'Antimalarial Drugs', in Compendium of Inflammatory Diseases, Springer Basel, Basel, pp. 97 - 101, http://dx.doi.org/10.1007/978-3-7643-8550-7
,2016, 'Coxibs', in Compendium of Inflammatory Diseases, Springer Basel, pp. 1 - 7, http://dx.doi.org/10.1007/978-3-0348-0620-6_22-1
,2016, 'Pharmacokinetics and metabolism of the salicylates', in Aspirin and Related Drugs, pp. 97 - 155
,2016, 'Antimalarial Drugs', in Compendium of Inflammatory Diseases, Springer Basel, pp. 97 - 101, http://dx.doi.org/10.1007/978-3-7643-8550-7_9
,2016, 'Coxibs', in Compendium of Inflammatory Diseases, Springer Basel, pp. 383 - 389, http://dx.doi.org/10.1007/978-3-7643-8550-7_22
,2016, 'Non-steroidal Anti-inflammatory Drugs: Overview', in Compendium of Inflammatory Diseases, Springer Basel, pp. 986 - 993, http://dx.doi.org/10.1007/978-3-7643-8550-7_52
,2016, 'Propionic Acid Derivative Drugs (Profens)', in Compendium of Inflammatory Diseases, Springer Basel, pp. 1106 - 1110, http://dx.doi.org/10.1007/978-3-7643-8550-7_58
,2016, 'Propionic Acid Derivative Drugs (Profens)', in Encyclopedia of Inflammatory Diseases, Springer Basel, pp. 1 - 6, http://dx.doi.org/10.1007/978-3-0348-0620-6_58-4
,2016, 'Salicylates', in Compendium of Inflammatory Diseases, Springer Basel, pp. 1169 - 1174, http://dx.doi.org/10.1007/978-3-7643-8550-7_62
,2013, 'Non-steroidal anti-inflammatory drugs', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
,2013, 'Propionic acid derivative drugs (Profens)', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
,2013, 'Salicylates', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
,2013, 'Urate-lowering therapy: Uricosurics', in Dalbeth N; Peresa-Ruiz F; Schlesinger N (ed.), Gout, Future Medicine Ltd, pp. 174 - 188, http://dx.doi.org/10.2217/ebo.13.104
,2013, 'Antimalarial Drugs', in Encyclopedia of Inflammatory Diseases, Springer Basel, pp. 1 - 6, http://dx.doi.org/10.1007/978-3-0348-0620-6_9-1
,2013, 'Non-steroidal Anti-inflammatory Drugs', in Encyclopedia of Inflammatory Diseases, Springer Basel, pp. 1 - 9, http://dx.doi.org/10.1007/978-3-0348-0620-6_52-2
,2013, 'NSAIDs and Their Indications', in Encyclopedia of Pain, Springer Berlin Heidelberg, pp. 2317 - 2322, http://dx.doi.org/10.1007/978-3-642-28753-4_2847
,2011, 'C15 Disease-modifying antirheumatic drugs', in Principles of Immunopharmacology, Birkhäuser Basel, pp. 585 - 619, http://dx.doi.org/10.1007/978-3-0346-0136-8_30
,2011, 'Disease modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 585 - 619, http://books.google.com.au/books?id=X0deXiGtcCAC&printsec=frontcover#v=onepage&q&f=false
,2011, 'Medication decision-making on hospital ward-rounds', in Moen A; Andersen SK; Aarts J; Hurlen P (ed.), Studies in Health Technology and Informatics, IOS Press, Amsterdam, pp. 935 - 939, http://dx.doi.org/10.3233/978-1-60750-806-9-935
,2005, 'Disease-modifying anti-rheumatic drugs (DMARD)', in Nijkamp FJ; Parnham MJ (ed.), Principles of Immunopharmacology (2nd Ed), Birkhauser Verlag, Basel, pp. 511 - 544
,2003, 'Therapy of osteoarthritis', in Scott D; Cope A (ed.), The Year in Rheumatic Disorders 2003, Clinical Publishibg Services Ltd, Oxford, United Kingdom, pp. 23 - 34
,2000, 'Connective tissue and bone disorders', in Melmon and Morrelli`s clinical pharmacology: basic principles in therapeutics, McGrath Hill, New York, pp. 645 - 702
,2000, 'Rheumatic Disorders', in Melmon and Morrelli`s clinical pharmacology: basic principles in therapeutics, McGrath Hill, New York, pp. 645 - 702
,2000, 'Rheumatoid arthritis. New Frontiers in pathogenesis and treatment', in NSAIDs and analgesics, Oxford University Press, Oxford, England, pp. 307 - 328
,1999, 'Are Intra-Articular steroids as effective?', in Challenges in Rheumatoid Arthritis, Blackwell Science, Oxford, UK, pp. 174 - 189
,1999, 'Disease-modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 379 - 403
,1998, 'Antirheumatic drugs and renal disease', in Rheumatology (2nd Ed), Gower, London, pp. 28 - 29
,1998, 'Arthritis', in Drug Therapy in old age, Wiley & Sons, Chichester UK, pp. 387 - 400
,1998, 'Disease Modifying antirheumatic drugs', in Textbook of Immunopharmacology, Burkhauser, Basel, Switzerland
,1998, 'Formulary and Guide to Prescribing (second edition)', in Formulary Guide to Prescribing (2nd Ed), St. Vincent's Hospital, Sydney, Australia, pp. 1 - 445
,1998, 'Non steroidal anti-inflammatory drugs and peptic ulceration', in Rheumatology (2nd Ed), Gower, London, pp. 27 - 28
,1998, 'SARDS', in Rheumatology (2nd Ed), Gower, London, pp. 8.1 - 8.10
,1998, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in Rainsford KD; Powanda MC (ed.), Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, Dordrecht
,1997, 'Guide to Clinically More Important Drug Interactions.', in Drug Safety, Adis International Limited, Auckland, New Zealand, pp. 1665 - 1700
,1997, 'Sulfasalazine.', in In: `The Textbook of Rheumatology`, Edition 5., pp. 741 - 746
,1997, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in In: `Safety and efficacy of non-prescription (OTC) analgesics, Kluwer Academic Publishers, Great Britain, pp. 77 - 92
,'NSAIDs and their Indications', in Encyclopedia of Pain, Springer Berlin Heidelberg, pp. 1460 - 1463, http://dx.doi.org/10.1007/978-3-540-29805-2_2847
,Journal articles
2024, 'The impact of a multi-faceted intervention on non-prescription dispensing of antibiotics by urban community pharmacies in Indonesia: a mixed methods evaluation', BMJ Global Health, 9, http://dx.doi.org/10.1136/bmjgh-2024-015620
,2024, 'A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease', British Journal of Clinical Pharmacology, 90, pp. 2529 - 2538, http://dx.doi.org/10.1111/bcp.16139
,2024, 'Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review', British Journal of Clinical Pharmacology, 90, pp. 2038 - 2066, http://dx.doi.org/10.1111/bcp.16164
,2024, 'Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout', Clinical Rheumatology, 43, pp. 2943 - 2954, http://dx.doi.org/10.1007/s10067-024-07050-y
,2024, 'A Longitudinal Study of the Use and Effects of Fall-Risk-Increasing Drugs in Residential Aged Care', Journal of the American Medical Directors Association, 25, http://dx.doi.org/10.1016/j.jamda.2024.105074
,2024, 'Evaluation of Published Population Pharmacokinetic Models to Inform Tacrolimus Therapy in Adult Lung Transplant Recipients', Therapeutic Drug Monitoring, 46, pp. 434 - 445, http://dx.doi.org/10.1097/FTD.0000000000001210
,2024, 'Developing a process to measure actual harm from medication errors in paediatric inpatients: From design to implementation', British Journal of Clinical Pharmacology, 90, pp. 1615 - 1626, http://dx.doi.org/10.1111/bcp.16052
,2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes, Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597
,2024, 'Patient factors and health outcomes associated with illness perceptions in people with gout', Rheumatology (United Kingdom), 63, pp. 1927 - 1937, http://dx.doi.org/10.1093/rheumatology/kead501
,